Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (13129)	8/12/1998 10:56:00 AM
From: VLAD	Read Replies (1) \| Respond to of 23519

Kahuna, IMO you are viewing these safety issues with rose colored glasses. Mark my words Kahuna, Pfizer is NOT going to be able to gloss over these issues. BTW Joe K on CNBS just discussed that PFE is down on the vision news--in typical proPfizer/antiVivus slant he incorrectly explained that he guessed it was due to a report that in CDV patients there was a temporary loss of vision. As I read the WSJ it was a PERMANENT loss of vision. Damn big difference but in classic CNBC slanted style again the public is deceived.